Eternal Youth: A Comprehensive Exploration of Gene, Cellular, and Pharmacological Anti-Aging Strategies
Open accessPublished version of a preprint
Abstract
The improvement of human living conditions has led to an increase in average life expectancy, creating a new social and medical problem—aging, which diminishes the overall quality of human life. The aging process of the body begins with the activation of effector signaling pathways of aging in cells, resulting in the loss of their normal functions and deleterious effects on the microenvironment. This, in turn, leads to chronic inflammation and similar transformations in neighboring cells. The cumulative retention of these senescent cells over a prolonged period results in the deterioration of tissues and organs, ultimately leading to a reduced quality of life and an elevated risk of mortality. Among the most promising methods for addressing aging and age-related illnesses are pharmacological, genetic, and cellular therapies. Elevating the activity of aging-suppressing genes, employing specific groups of native and genetically modified cells, and utilizing senolytic medications may offer the potential to delay aging and age-related ailments over the long term. This review explores strategies and advancements in the field of anti-aging therapies currently under investigation, with a particular emphasis on gene therapy involving adeno-associated vectors and cell-based therapeutic approaches.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED: New intranasal and injectable gene therapy for healthy life extension
Jaijyan, D. K., Selariu, A., Cruz-Cosme, R., Tong, M., Yang, S., Stefa, A., Kekich, D., Sadoshima, J., Herbig, U., Tang, Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121499119 · Cited by 57 · see citing works
RetractedOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · cited 1× · see citing works
“It was found that transfection of oncogenic HRAS (V12 mutation) into mouse, rat, and human embryonic fibroblasts resulted in the arrest of cell proliferative activity [28,29].”
BackgroundClearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 1× · see citing works
“It is known that deletion of p16-positive senescent cells delays the onset and progression of age-related pathologies in mice in vivo and prolongs the lifespan of prematurely and naturally aging mice [32,33].”
BackgroundNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,891 · cited 1× · see citing works
“It is known that deletion of p16-positive senescent cells delays the onset and progression of age-related pathologies in mice in vivo and prolongs the lifespan of prematurely and naturally aging mice [32,33].”
BackgroundThe Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,562 · cited 1× · see citing works
“These include the SRC tyrosine kinase inhibitor dasatinib, which has been approved and widely used since 2006 with a relatively good safety profile, as well as the natural flavonoids quercetin and fisetin (refer to Table 1) [53].”
BackgroundA complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278 · cited 1× · see citing works
“…senescent cells exhibit increased β -galactosidase activity (referred to as senescence-associated β -galactosidase, SA-β -gal is one of the widely used markers of aged cells) at pH 6.0, activation of signaling pathways, and secretion of various growth factors, chemokines, and cytokines [35].”
BackgroundInfluentialL1 drives IFN in senescent cells and promotes age-associated inflammation
De Cecco, M., Ito, T., Petrashen, A. P., Elias, A. E., Skvir, N. J., Criscione, S. W., Caligiana, A., Brocculi, G., Adney, E. M., Boeke, J. D., et al. (2019) · Nature · doi:10.1038/s41586-018-0784-9 · Cited by 1,255 · see citing works
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,105 · cited 2× · see citing works
“…activation (Na + /K + -ATPase), SASP inhibitor drugs, and induction of clearance of senescent cells by antibody–drug conjugates, vaccination, and cell therapy based on chimeric antigen receptor synthesizing T cells (CAR T cells), which will also be mentioned in the cell therapy section [54].”
BackgroundSenolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098 · see citing works
Jaul, E., & Barron, J. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00335 · Cited by 946 · see citing works
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777 · see citing works
Zhu, Y., Doornebal, E. J., Pirtskhalava, T., Giorgadze, N., Wentworth, M., Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., Robbins, P. D., Tchkonia, T., & Kirkland, J. L. (2017) · Aging · doi:10.18632/aging.101202 · Cited by 757 · see citing works
Organ aging signatures in the plasma proteome track health and disease
Oh, H. S.-H., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., Channappa, D., Urey, D. Y., Kim, K., Sung, Y. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06802-1 · Cited by 634 · see citing works
Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality
Tian, Y. E., Cropley, V., Maier, A. B., Lautenschlager, N. T., Breakspear, M., & Zalesky, A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02296-6 · Cited by 618 · see citing works
Ortiz-Montero, P., Londoño-Vallejo, A., & Vernot, J.-P. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0172-3 · Cited by 428 · see citing works
Identification and characterization of Cardiac Glycosides as senolytic compounds
Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12888-x · Cited by 384 · see citing works
McConnell, B. B., Starborg, M., Brookes, S., & Peters, G. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70137-x · Cited by 314 · see citing works
IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis
Faust, H. J., Zhang, H., Han, J., Wolf, M. T., Jeon, O. H., Sadtler, K., Peña, A. N., Chung, L., Maestas, D. R., Tam, A. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134091 · Cited by 260 · see citing works
mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53
Jung, S. H., Hwang, H. J., Kang, D., Park, H. A., Lee, H. C., Jeong, D., Lee, K., Park, H. J., Ko, Y.-G., & Lee, J.-S. (2019) · Oncogene · doi:10.1038/s41388-018-0521-8 · Cited by 166 · see citing works
Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Wang, L., Wang, B., Gasek, N. S., Zhou, Y., Cohn, R. L., Martin, D. E., Zuo, W., Flynn, W. F., Guo, C., Jellison, E. R., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.002 · Cited by 163 · see citing works
The role of cellular senescence and SASP in tumour microenvironment
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2023) · The FEBS Journal · doi:10.1111/febs.16381 · Cited by 144 · cited 1× · see citing works
“…kinase 4A, is specifically activated in senescent cells and suppresses CDK4/6, thereby inducing senescence-associated cell cycle arrest in the G0/1 phase, which depends on the dephosphorylation of retinoblastoma Rb family proteins (Rb, p107 and p130), which are known targets of CDK4/6 [30].”
BackgroundYoum, Y.-H., Horvath, T. L., Mangelsdorf, D. J., Kliewer, S. A., & Dixit, V. D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514511113 · Cited by 129 · see citing works
Flagged first, then by citations
- Authors
- Kitaeva, K. V., Solovyeva, V. V., Blatt, N. L., & Rizvanov, A. A.
- Affiliations
- Kazan Federal University (RU)
- Corresponding author
- Rizvanov, Albert A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-01-04
- Volume
- 25
- Issue
- 1
- Pages
- 643
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10778954
- OpenAlex
- W4390586638
- Cited by
- 7
- References
- 22
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Kazan Federal University (FZSM-2023-0011)
- Topics
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- anti-aging therapy, cellular senescence, senolytics, aging, age-related diseases, gene therapy, adeno-associated virus vectors, cell therapy, chronic inflammation
- MeSH terms
- Adolescent, Aging, Humans, Life Expectancy, Quality of Life, Genetic Therapy, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
